Search results
Results from the WOW.Com Content Network
In July 2015, pembrolizumab received marketing approval in the European Union. [19] [61] [13] In October 2015, the US FDA approved pembrolizumab for the treatment of metastatic non-small cell lung cancer (NSCLC) in people whose tumors express PD-L1 and who have failed treatment with other chemotherapeutic agents. [62] [63] [64]
Pembrolizumab (Keytruda, formerly MK-3475 and lambrolizumab) was developed by Merck and first approved by the Food and Drug Administration in 2014 for the treatment of melanoma. It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma .
Tissue-agnostic cancer drugs are antineoplastic drugs that treat cancers based on the mutations that they display, instead of the tissue type in which they appear. [1] [2] [3] Tissue-agnostic drugs that have been approved for medical use include Pembrolizumab, Larotrectinib, Selpercatinib, Entrectinib, and Pralsetinib.
Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with ...
Concurrently, on Wednesday, Japan’s drug regulator approved new indications for Keytruda (pembrolizumab), in certain lung and urothelial cancers. Merck Stock Prediction For 2024
It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [16] Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [17]
GoodRx released a list of 19 of the most influential drugs and vaccines approved by the FDA in 2024 to treat a variety of conditions. These medications are “slated to make a big clinical impact."
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more